NOVARTIS PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVARTIS PHARM, and when can generic versions of NOVARTIS PHARM drugs launch?
NOVARTIS PHARM has five approved drugs.
There are fourteen US patents protecting NOVARTIS PHARM drugs.
There are three hundred and fifty-one patent family members on NOVARTIS PHARM drugs in fifty-four countries and ninety-two supplementary protection certificates in seventeen countries.
Summary for NOVARTIS PHARM
International Patents: | 351 |
US Patents: | 14 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Patent Litigation for NOVARTIS PHARM: | See patent lawsuits for NOVARTIS PHARM |
Drugs and US Patents for NOVARTIS PHARM
Expired US Patents for NOVARTIS PHARM
Paragraph IV (Patent) Challenges for NOVARTIS PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
International Patents for NOVARTIS PHARM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 201506060 | ⤷ Try a Trial |
Russian Federation | 2459809 | ⤷ Try a Trial |
Canada | 2954840 | ⤷ Try a Trial |
Malaysia | 187276 | ⤷ Try a Trial |
Norway | 20151656 | ⤷ Try a Trial |
Spain | 2823749 | ⤷ Try a Trial |
Japan | 2008542447 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVARTIS PHARM Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1467728 | 16C0019 | France | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN,Y COMPRIS LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1058 20151123 |
2269604 | 62/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001-006 20090805 |
2340828 | 2021C/502 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, I.E. (((S)-N-VALERYL-N-((2'-(1H-TETRAZOL-5-YL)-BIFENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIFENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTAANZUURETHYLESTER))NA3 . X H2O, WAARBIJ X 0 TOT 3 IS; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 (C(2015) 8288) 20151123 |
3143995 | LUC00122 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001, 003, 004, 006-010 20160530 |
2269603 | 132015000073030 | Italy | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS O UN SUO SALE FARMACEUTICAMENTE ACCCETTABILE(AFINITOR); AUTHORISATION NUMBER(S) AND DATE(S): C(2012)5347, 20120725 |
0663916 | SPC/GB10/003 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; REGISTERED: SE SE 18690-18695 20030718; UK EU/1/09/538/001 20090803; UK EU/1/09/538/002 20090803; UK EU/1/09/538/003 20090803; UK EU/1/09/538/004 20090803; UK EU/1/09/538/005 20090803; UK EU/1/09/538/006 20090803 |
2269604 | C02269604/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS (40-O-(2-HYDROXYETHYL)-RAPAMYCIN); REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 59174 17.11.2009 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.